Bakelite Synthetics Achieves Responsible Care® Certification
ATLANTA--(BUSINESS WIRE)--Apr 22, 2025--
Bakelite Synthetics ('the Company') announced the successful completion of the American Chemistry Council's Responsible Care ® certification process, achieving compliance at all of our U.S. sites. Responsible Care is the global chemical manufacturing industry's leading safety and sustainability initiative, driving continual improvement in environmental, health, safety, and security performance.
Being a Responsible Care partner is crucial as it underscores the Company's commitment to environmental sustainability, community wellbeing, and regulatory compliance. This certification builds trust and loyalty among customers and stakeholders, enhances associate engagement, and supports long-term business success through innovative and sustainable practices.
JP Aucoin, President and Chief Executive Officer of Bakelite Synthetics, stated, 'Achieving Responsible Care certification is a testament to our commitment to safety, sustainability, and continuous improvement. We are proud of our team's dedication to these principles and look forward to continuing our journey towards a more sustainable future.'
About Bakelite Synthetics
Based in Atlanta, Georgia, Bakelite Synthetics is a leading global integrated producer of thermoset specialty resins, solutions and engineered thermoset molding compounds serving a variety of segments and end markets across geographies. Additional information about Bakelite Synthetics and its products is available at bakelite.com.
About Responsible Care
Launched in Canada 1985, Responsible Care has grown to nearly 70 global economies. Each national chemical association manages its own Responsible Care program, based on eight common fundamental features developed by the International Council of Chemical Associations (ICCA):
View source version on businesswire.com:https://www.businesswire.com/news/home/20250422370374/en/
CONTACT: Bakelite Media Contact:
John Branham
(404) 749-2516
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: ENGINEERING CHEMICALS/PLASTICS ENVIRONMENT MANUFACTURING SUSTAINABILITY OTHER MANUFACTURING
SOURCE: Bakelite Synthetics
Copyright Business Wire 2025.
PUB: 04/22/2025 09:41 AM/DISC: 04/22/2025 09:41 AM
http://www.businesswire.com/news/home/20250422370374/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
41 minutes ago
- Business Wire
KBRA Releases Global ABS 2025: Day 3 Recap
LONDON--(BUSINESS WIRE)--KBRA releases a Day 3 recap of the 29th annual Global ABS conference. The third and final day of the Global ABS 2025 conference focused on private credit and featured a series of engaging roundtable discussions. Highlights included a fireside chat and discussion among several industry legends. Topics covered included net asset value (NAV) lending, asset-based finance (ABF), and broader trends in private credit. Click here to view a recap of some of the day's panel discussions. Recent Publications About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009820
Business Upturn
an hour ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
Resolutions of the shareholders of Hepsor AS – adoption of resolutions of the general meeting without calling a meeting
The management board of Hepsor AS, registry code 12099216 (hereinafter the Company) published on 5 June 2025 pursuant to § 2991 subsections 1, 2 and 3 of the Commercial Code the draft resolutions for the adoption of shareholders' resolutions without calling a meeting. The list of shareholders entitled to vote was determined as at seven days before the voting term, i.e. on 5 June 2025 at the end of the business day of the settlement system of Nasdaq CSD Estonia. The Company has a total of 9,142 shareholders, who own a total of 3,854,701 shares. The deadline for shareholders to submit their positions was on 12 June 2025 at 23:59 Estonian time. Six shareholders of the Company submitted their vote, whose shares represent in total 2,978,700 votes, that forms 77.27% of all votes determined by shares. The shareholders of the Company adopted the following resolutions Approval of the acquisition of a minority shareholding in Hepsor Latvia OÜ To approve the transaction whereby the Company acquires the share of Hepsor Latvia OÜ from Hugomon OÜ, which represents 20% of the share capital of Hepsor Latvia OÜ, on the following main terms and conditions: The Company will pay 20,000 euros in cash to Hugomon OÜ for the share of Hepsor Latvia OÜ and will issue 57,821 shares of the Company to Hugomon OÜ, whereas upon the issue of the Company's shares, Hugomon OÜ will pay for the shares with the share of Hepsor Latvia OÜ as a non-monetary contribution; By amending the articles of association, the Supervisory Board of the Company is given the right to increase the share capital of the Company and to issue new shares to Hugomon OÜ; The subscription right for the new shares will be given to Hugomon OÜ and the pre-emptive subscription right of the existing shareholders will be excluded. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Amendment of the articles of association To amend the articles of association of the Company and adopt the articles of association of the Company in the new wording, in the form presented to the general meeting. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Exclusion of pre-emptive subscription rights To exclude the Company's shareholders' pre-emptive subscription rights upon the increase of the share capital and the issuance of 57,821 new shares in connection with the acquisition of the share of Hepsor Latvia OÜ from Hugomon OÜ. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Additional information: Henri LaksMember of the management boardTel: +372 5693 9114E-mail: henri@ Hepsor AS ( is a developer of residential and commercial real estate. The Group operates in Estonia, Latvia and Canada. During our fourteen years of operation, we have created 2,076 homes and nearly 36,300 m2 of commercial space. As the first developer in the Baltic countries, Hepsor has implemented several innovative engineering and technical solutions that make the buildings built by the company more energy-efficient and thus more environmentally friendly. The company's portfolio includes a total of 25 development projects with a total area of 172,800 m2.
